AHL Partners’s NovoCure NVCR Stock Holding History

AHL Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,639	Closed	-$231K	–	1331
2017 Q3	$231K	Buy	+11,639	New	+$229K	﹤0.01%	1189

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

AHL Partners's NVCR Position: Q4 2017 in Review

AHL Partners sold out of NovoCure (NVCR) in Q4 2017, closing a stake of 11,639 shares — an estimated $231K sold.

AHL Partners first reported a position in NVCR in Q3 2017 and held it in 1 quarter. The position peaked at $231K in Q3 2017. 128 funds tracked by Wall St. Rank hold NVCR as of Q4 2017.

AHL Partners reported no remaining NovoCure position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 11,639 NovoCure shares in Q4 2017, an estimated $231K.
AHL Partners first reported a position in NovoCure in Q3 2017 and held it in 1 quarter.
AHL Partners's NovoCure position peaked at $231K in Q3 2017.
128 funds tracked by Wall St. Rank held NovoCure as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.